skip to Main Content

Transcriptionally Distinct B Cells Infiltrate Allografts After Kidney Transplantation

Zhang, Hengcheng MD, PhD; Cavazzoni, Cecilia B. PhD; Hanson, Benjamin L.; Bechu, Elsa D.; Podestà, Manuel A. MD; Azzi, Jamil MD; Blazar, Bruce R. MD; Chong, Anita S. PhD; Kreisel, Daniel MD, PhD; Alessandrini, Alessandro PhD; Sage, Peter T. PhD

In this manuscript Dr. Sage’s team assessed the transcriptional programming and origins of intragraft B cells after kidney transplantation. They found that graft infiltrating B cells are innate-like transcriptionally and likely do not originate from lymph node germinal center B cells.

Transplantation 107(2):p e47-e57, February 2023. | DOI: 10.1097/TP.0000000000004398

May, 2023

Follicular T cells Optimize the Germinal Center Response to SARS-CoV-2 Protein Vaccination in Mice

Follicular T cells Optimize the Germinal Center Response to SARS-CoV-2 Protein Vaccination in Mice

Cavazzoni CB, Hanson BL, Podesta MA, Bechu ED, Clement RL, Zhang H, Daccache J, Reyes-Robles T, Hett EC, Vora KA, Fadeyi OO, Oslund RC, Hazuda DJ, Sage PT

Cell Reports, Feb. 2022

In this manuscript Dr. Sage’s team studied how follicular T cells control antibody responses during SARS-CoV-2 vaccination. Using genetic deletion studies and natural settings of aging they show that follicular T cells delicately balance affinity maturation and clonal expansion to optimize vaccine responses.

May, 2022

Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection

Paolo Fiorina et. al.

May, 2021

Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater prevalence of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory syndrome coronavirus 2 infection may precipitate the onset of metabolic alterations by affecting glucose homeostasis. Here we describe abnormalities in glycometabolic control, insulin resistance and beta cell function in patients with COVID-19 without any pre-existing history or diagnosis of diabetes, and document glycaemic abnormalities in recovered patients 2 months after onset of disease. In a cohort of 551 patients hospitalized for COVID-19 in Italy, we found that 46% of patients were hyperglycaemic, whereas 27% were normoglycaemic. Using clinical assays and continuous glucose monitoring in a subset of patients, we detected altered glycometabolic control, with insulin resistance and an abnormal cytokine profile, even in normoglycaemic patients. Glycaemic abnormalities can be detected for at least 2 months in patients who recovered from COVID-19. Our data demonstrate that COVID-19 is associated with aberrant glycometabolic control, which can persist even after recovery, suggesting that further investigation of metabolic abnormalities in the context of long COVID is warranted.

Donor myeloid derived suppressor cells (MDSCs) prolong allogeneic cardiac graft survival through programming of recipient myeloid cells in vivo

April, 2021

Solid organ transplantation is a lifesaving therapy for patients with end-organ disease. Current immunosuppression protocols are not designed to target antigen-specific alloimmunity and are uncapable of preventing chronic allograft injury.

Follicular T cells mediate donor-specific antibody and rejection after solid organ transplantation

Mostafa Mohammed et. al.

January, 2021

Following solid organ transplantation, a substantial proportion of chronic allograft loss is attributed to the formation of donor-specific antibodies (DSAs) and antibody-mediated rejection (AbMR).

A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant

Naoka Murakami et. al.

December, 2020

Immune checkpoint inhibitors (ICIs) are widely used for various malignancies. However, their safety and efficacy in patients with a kidney transplant have not been defined. To delineate this, we conducted a multicenter retrospective study of 69 patients with a kidney transplant receiving ICIs between January 2010 and May 2020.

Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy

Liwei Jiang et. al.

November, 2020

Cancer therapies kill tumors either directly or indirectly by evoking immune responses and have been combined
with varying levels of success. Here, we describe a paradigmto control cancer growth that is based on
both direct tumor killing and the triggering of protective immunity.

Regulatory T cells engineered with TCR signaling–responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter

Siawosh K Eskandari et. al.

November, 2020

Adoptive cell transfer of ex vivo expanded regulatory T cells (Tregs) has shown immense potential in animal models of auto- and alloimmunity. However, the effective translation of such Treg therapies to the clinic has been slow.

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

Sebastiano Bruno Solerte, Francesca D’Addio, Roberto Trevisan, Elisabetta Lovati, Antonio Rossi, Ida Pastore, Marco Dell’Acqua, Elio Ippolito, Cristiana Scaranna, Rosalia Bellante, Silvia Galliani, Alessandro Roberto Dodesini, Giuseppe Lepore, Francesca Geni, Roberta Maria Fiorina, Emanuele Catena, Angelo Corsico, Riccardo Colombo, Marco Mirani, Carlo De Riva, Salvatore Endrio Oleandri, Reza Abdi, Joseph V. Bonventre, Stefano Rusconi, Franco Folli, Antonio Di Sabatino, Gianvincenzo Zuccotti, Massimo Galli1 and Paolo Fiorina

September, 2020

Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population.

Lymph node fibroblastic reticular cells deposit fibrosis-associated collagen following organ transplantation

Xiaofei Li et. al.

August, 2020

Although the immune response within draining lymph nodes (DLNs) has been studied for decades, how their stromal compartment contributes to this process remains to be fully explored. Here, we show that donor mast cells were prominent activators of collagen I deposition by fibroblastic reticular cells (FRCs) in DLNs shortly following transplantation.

Back To Top